Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
40.47B
Market cap40.47B
Price-Earnings ratio
72.01
Price-Earnings ratio72.01
Dividend yield
Dividend yield
Average volume
1.06M
Average volume1.06M
High today
$310.38
High today$310.38
Low today
$297.53
Low today$297.53
Open price
$304.62
Open price$304.62
Volume
1.00M
Volume1.00M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$283.10
52 Week low$283.10

Stock Snapshot

With a market cap of 40.47B, Alnylam Pharmaceuticals(ALNY) trades at $297.53. The stock has a price-to-earnings ratio of 72.01.

As of 2026-06-07, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $297.53 and $310.38. The current price stands at $297.53, placing the stock 0.0% above today's low and -4.1% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1M, compared to an average daily volume of 1.06M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $283.10 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $283.10 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 23h
How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals Has Changed Its Investment Story

On June 3, 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a collaboration worth up to US$2.00 billion, including US$30 million upfront in cash a...

How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals Has Changed Its Investment Story
Benzinga 3d
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion

The partnership aims to enhance the discovery of RNA interference (RNAi) therapeutics by integrating Alnylam’s RNAi platform with Inceptive’s AI expertise, pote...

Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion
Simply Wall St 3d
AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has announced a new collaboration with AI firm Inceptive Nucleics focused on accelerating RNAi drug discovery. The part...

AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

More ALNY News

Nasdaq 3d
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced partnership with Inceptive Nucleics, Inc., an artificial intelligence-driven biotechnology company, i...

Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln
TipRanks 3d
Alnylam, Inceptive form strategic AI collaboration

The company states: “Alnylam (ALNY) Pharmaceuticals and Inceptive Nucleics, Inc. announced a strategic collaboration agreement to increase the pace of therapeut...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.